We could all use a laugh in these uncertain times. If you’re a person with Alzheimer’s disease, a family member, or caregiver, you can join LaughterOnCall for their virtual Lunchtime Laughter meetings, Monday-Friday at 12 PM PST. This webinar offers a light-hearted, engaging way to laugh and cope with feelings of isolation that can come from social distancing. To register, visit https://zoom.us/meeting/register/uZEtdemurzIq_pN_HCQ7TY2I8cpa4NsoGQ OR e-mail info@laughteroncall.com to sign up. LaughterOnCall may record these meetings for quality purposes.
Read More
We’re pleased to announce the “Focus on Aging” webinar series with the Administration for Community Living, the Centers for Disease Control and Prevention, the Health Resources and Services Administration, and the National Institute on Aging. The first webinar, “Supporting Older Adults in Emergencies: Preparedness, Response, and Recovery” will be held May 13 at 1:30-3:00 p.m. ET. Register today! https://www.nia.nih.gov/alzheimers/focus-aging-federal-partners-webinar-series A message from: Nina Silverberg, PhD Director, Alzheimer's Disease Centers Program Division of Neuroscience National Institute on Aging National Institutes of Health
Read More
Contributed by Edwin Monuki, MD, PhD, Warren L. Bostick Professor and Chair of Pathology and Laboratory Medicine at UC Irvine A recent article in the The New York Times focuses on an issue of grave concern among US health care providers - the flood of unapproved “lateral flow” tests for detecting COVID-19 antibodies. This flood resulted from an FDA decision to allow antibody testing without their usual approval process in order to accelerate the national response to COVID-19. Unfortunately (and not surprisingly), this also resulted in an antibody testing market that one interviewee in the NYT article called the “Wild West”.…
Read More
NPR reports May 1, 2020 4:22 PM ET - The Food and Drug Administration has given emergency use authorization to the antiviral drug remdesivir to treat hospitalized patients with the coronavirus, President Trump on Friday told reporters at the White House. Gilead CEO Daniel O'Day said remdesivir maker Gilead Sciences is donating 1.5 million vials of the drug and will work with the federal government to distribute it to patients in need...
Read More
ASK THE DOC! UCI MIND Facebook LIVE Video Series This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. Alzheimer's disease, clinical trials, and COVID-19 About the Speaker: Dr. Gillen received his PhD in Biostatistics from the University of Washington and leads the Data Management and Statistics Core for UCI MIND’s NIH-designated…
Read More
HHS launched https://telehealth.hhs.gov. This site is a central source of information on telehealth resources and tools for patients and providers.
Read More
Over the weekend, the CDC added six new coronavirus symptoms to its list. The new symptoms include chills, repeated shaking with chills, muscle pain, headache, sore throat and a loss of taste or smell. Watch for symptoms People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms or combinations of symptoms may have COVID-19: Cough Shortness of breath or difficulty breathing Or at least two of these symptoms: Fever Chills Repeated shaking with chills Muscle pain…
Read More
Alzheimer's disease, clinical trials, and COVID-19 Join UCI MIND for a live Q&A on Facebook with Dr. Daniel Gillen, Professor and Chair of Statistics at UC Irvine, this Friday, May 1st at 11:00-11:30 AM PST. About the Speaker: Daniel Gillen received his PhD in Biostatistics from the University of Washington and leads the Data Management and Statistics Core for UCI MIND’s NIH-designated Alzheimer’s Disease Research Center. He is an elected fellow of the American Statistical Association and widely recognized for his work in the design and analysis of clinical trials for Alzheimer’s disease and other health conditions. Dr. Gillen serves…
Read More
The County of Orange Social Services Agency (SSA) announced the creation of a hotline for current In-Home Supportive Services (IHSS) recipients. The hotline staff will be available to discuss recipients’ urgent needs during the coronavirus pandemic. Recipients can call (714) 825-3000 and press option 4.
Read More
https://youtu.be/r4ZpVGrBw5o Nicole Schartz, PhD, a postdoctoral scholar in Dr. Andrea Tenner’s lab, shares her experience of what’s happening in her lab and her perspective on the pandemic. Dr. Schartz is also a member of REMIND. Research and Education in Memory Impairments and Neurological Disorders, or REMIND, is a campus organization led by UCI MIND predoctoral and postdoctoral trainees. It aims to encourage collaboration among the next generation of scientists and clinicians, and promote community outreach and education on neurodegenerative diseases.
Read More
